Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for TRPV6-Targeted Oncology and Inflammatory Disease Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TRPV6 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TRPV6 Extracellular Loop Recombinant Protein High purity (>90%), Endotoxin Controlled. Sequence Verified. Designed for antibody immunization and binding assays. |
View TRPV6 Products |
| Gene Delivery | TRPV6 Promise-ORF / Lentivirus Full-length human TRPV6 ORF. Ideal for generating stable overexpressing cell lines for calcium flux and patch-clamp assays. |
View TRPV6 Products |
| Benchmark Ab | Anti-TRPV6 Recombinant Antibody Recombinant positive control derived from literature-validated clones for FACS, IHC, and functional blocking. |
View TRPV6 Products |
| Validator | TRPV6 siRNA Set Target-specific siRNA pool for target knockdown and specificity validation in cell-based assays. |
View TRPV6 Products |
| Related Target A | TRPV5 Highly homologous counter-screening target (75% identity). Crucial for verifying off-target renal toxicity profiles. |
View TRPV5 Products |
| Related Target B | ORAI1 Partner calcium channel in the store-operated calcium entry (SOCE) pathway, frequently co-targeted in calcium-dependent cancers. |
View ORAI1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| TRPV5 Off-Target Counter-Screening | Human TRPV5 and TRPV6 ortholog reagents available with strict identity verification by Mass Spectrometry. |
| Conformational Integrity for Ion Channels | Lentivirus-based stable cell line development tools bypass VLP limitations, preserving native tetrameric channel structures. |
| Lack of Reference Controls | Sequence-verified clinical-grade reference antibodies and specific small-molecule control pathways supported. |
| Assay Noise in Calcium Flux | High-titer, mycoplasma-free Lentiviral vectors ensure robust, reproducible expression levels in HEK293/CHO host cells. |
Live TRPV6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TRPV6 therapeutics is intensifying, with major players shifting focus from traditional non-selective calcium channel blockers to highly selective small molecules and peptide-drug conjugates (PDCs). TRPV6 is markedly overexpressed in several epithelial cancers (including prostate, breast, ovarian, and pancreatic cancers) where it drives the calcium-dependent signaling cascades essential for tumor progression and metastasis.
As first-generation TRPV6 inhibitors like SOR-C13 (a peptide derived from short-tailed shrew venom) progress through clinical trials, the next wave of R&D is targeting small-molecule allosteric modulators and monoclonal antibodies. The primary clinical hurdle remains systemic toxicity—specifically hypercalciuria and renal issues caused by off-target inhibition of the closely related TRPV5 channel. Consequently, developers are prioritizing ultra-selective screening assays to isolate candidates that distinguish TRPV6 from its renal counterpart.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptides (PDCs) | Soricimed Biopharma | Solid Tumors (Ovarian, Pancreatic) | Targeted Binding Assays (Need high-purity extracellular loop proteins) |
| Small Molecules | Academic institutions, Biotech startups | Prostate Cancer, Breast Cancer | Selectivity & Functional Assays (Need TRPV6 vs TRPV5 Lentiviral expression systems) |
| Monoclonal Antibodies | Emerging oncology biopharma | Advanced Epithelial Cancers | Epitope Mapping & Flow Cytometry (Need native conformation cell lines) |